/PRNewswire/ Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology,.
/PRNewswire/ Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company focused on developing novel drugs for inflammation, fibrosis and oncology,.
The oral antiviral Molnupiravir is going to be supplied by five Indian pharmaceutical companies who have signed licensing agreements with the parent company
/PRNewswire/ Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle.
/PRNewswire/ Bridge Biotherapeutics (KQ288330) today announced the first patient dosing of BBT-401 in its open label, proof of mechanism study to examine.